Targeting heat shock protein 90 with non-quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma

Hepatology

Volumn 50, Issue 1, 2009, Pages 102-112

  Breinig, Marco ^a   Caldas Lopes, Eloisi ^b   Goeppert, Benjamin ^a   Malz, Mona ^a   Rieker, Ralf ^a,c   Bergmann, Frank ^a   Schirmacher, Peter ^a   Mayer, Matthias ^d   Chiosis, Gabriela ^b   Kern, Michael André ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; 8 (6 IODOBENZO[D][1,3]DIOXOL 5 YLTHIO) 9 [3 (ISOPROPYLAMINO)PROPYL] 9H PURIN 6 AMINE; HEAT SHOCK PROTEIN 90 INHIBITOR; PU H71; TANESPIMYCIN; UNCLASSIFIED DRUG; HEAT SHOCK PROTEIN 90; QUINONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG CLEARANCE; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TOXICITY TESTING; TUMOR XENOGRAFT; ANIMAL; DRUG ANTAGONISM; LIVER TUMOR; TUMOR CELL CULTURE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LIVER NEOPLASMS; MICE; QUINONES; TUMOR CELLS, CULTURED;

EID: 67651160909     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22912     Document Type: Article

References (43)

1. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007;1113:202-216. (Pubitemid 350015011)
2. Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008;410:439-453.
3. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-772.
4. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-410. (Pubitemid 37187270)
5. Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H, et al. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem Biol 2004;11:787-797. (Pubitemid 38836895)
6. Zhang H, Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 2004;82:488-499. (Pubitemid 39149859)
7. Pascale RM, Simile MM, Calvisi DF, Frau M, Muroni MR, Seddaiu MA, et al. Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer. HEPATOLOGY 2005;42:1310-1319.
8. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. HEPATOLOGY 2008;48:1312-1327.
9. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576. (Pubitemid 46890874)
10. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004;5:215-219.
11. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-687. (Pubitemid 44286000)
12. Rodina A, Vilenchik M, Moulick K, Aguirre J, Kim J, Chiang A, et al. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nat Chem Biol 2007;3:498-507. (Pubitemid 47080368)
13. Tsuji T, Miyazaki M, Fushimi K, Mihara K, Inoue Y, Ohashi R, et al. Cyclin E overexpression responsible for growth of human hepatic tumors with p21WAF1/CIP1/SDI1. Biochem Biophys Res Commun 1998;242: 317-321. (Pubitemid 28412425)
14. Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR, Ozturk M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci U S A 1990;87:1973-1977. (Pubitemid 20098095)
15. Schleger C, Heck R, Niketeghad F, Schirmacher P, Radaeva S, Oesch F, et al. Establishment and characterization of a nontumorigenic cell line derived from a human hepatocellular adenoma expressing hepatocyte-specific markers. Exp Cell Res 1997;236:418-426. (Pubitemid 27505594)
16. Breinig M, Rieker R, Eiteneuer E, Wertenbruch T, Haugg AM, Helmke BM, et al. Differential expression of E-prostanoid receptors in human hepatocellular carcinoma. Int J Cancer 2008;122:547-557. (Pubitemid 350308945)
17. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002;8:986-993. (Pubitemid 34517631)
18. Hollingshead M, Alley M, BurgerAM,Borgel S, Pacula-Cox C, FiebigHH,et al. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino- 17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol 2005;56:115-125.
19. Cysyk RL, Parker RJ, Barchi JJ Jr, Steeg PS, Hartman NR, Strong JM. Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. Chem Res Toxicol 2006;19:376-381.
20. Guo W, Reigan P, Siegel D, Ross D. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin Hsp90 inhibitors: relevance for toxicity and mechanism of action. Drug Metab Dispos 2008;36:2050-2057.
21. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-776.
22. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001; 61:4003-4009. (Pubitemid 32720963)
23. Srethapakdi M, Liu F, Tavorath R, Rosen N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res 2000;60:3940-3946. (Pubitemid 32204590)
24. Whitesell L, Bagatell R, Falsey R. The stress response: implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets 2003; 3:349-358. (Pubitemid 37128321)
25. Nylandsted J, Wick W, Hirt UA, Brand K, Rohde M, Leist M, et al. Eradication of glioblastoma, and breast and colon carcinoma xenografts by Hsp70 depletion. Cancer Res 2002;62:7139-7142. (Pubitemid 36025225)
26. Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 1998;94:471-480. (Pubitemid 28391863)
27. Guo F, Rocha K, Bali P, Pranpat M, Fiskus W, Boyapalle S, et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 2005;65:10536-10544. (Pubitemid 41743748)
28. Kern MA, Breuhahn K, Schirmacher P. Molecular pathogenesis of human hepatocellular carcinoma. Adv Cancer Res 2002;86:67-112.
29. Thorgeirsson SS, Lee JS, Grisham JW. Functional genomics of hepatocellular carcinoma. HEPATOLOGY 2006;43:S145-S150.
30. Lee JS, Thorgeirsson SS. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology 2004;127:S51-S55.
31. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359: 378-390.
32. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006;116:1582-1595. (Pubitemid 43911012)
33. Nussbaum T, Samarin J, Ehemann V, Bissinger M, Ryschich E, Khamidjanov A, et al. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. HEPATOLOGY 2008;48:146-156. (Pubitemid 351975539)
34. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. HEPATOLOGY 2007;45:42-52. (Pubitemid 46144363)
35. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-1949.
36. Tada M, Yokosuka O, Fukai K, Chiba T, Imazeki F, Tokuhisa T, et al. Hypermethylation of NAD(P)H: quinone oxidoreductase 1 (NQO1) gene in human hepatocellular carcinoma. J Hepatol 2005;42:511-519. (Pubitemid 40342930)
37. Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 2008;14:240-248.
38. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008; 68:2850-2860. (Pubitemid 351556284)
39. Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007;13:1775-1782. (Pubitemid 46952945)
40. Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, et al. A phase I trial of twice-weekly 17-allylamino-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2006;12: 6087-6093. (Pubitemid 44703773)
41. Taldone T, Gozman A, Maharaj R, Chiosis G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 2008;8:370-374.
42. Hu J, Flores D, Toft D, Wang X, Nguyen D. Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function. J Virol 2004;78:13122-13131. (Pubitemid 39507819)
43. Nakagawa S, Umehara T, Matsuda C, Kuge S, Sudoh M, Kohara M. Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochem Biophys Res Commun 2007;353:882-888. (Pubitemid 46080379)